Urotrast en es it fr

Urotrast Brand names, Urotrast Analogs

Urotrast Brand Names Mixture

  • No information avaliable

Urotrast Chemical_Formula

C9H15N5O3

Urotrast RX_link

No information avaliable

Urotrast fda sheet

Urotrast msds (material safety sheet)

Urotrast Synthesis Reference

No information avaliable

Urotrast Molecular Weight

241.247 g/mol

Urotrast Melting Point

250-255 oC (hydrochloride salt)

Urotrast H2O Solubility

>20 mg/mL (dichloride salt)

Urotrast State

Solid

Urotrast LogP

-1.783

Urotrast Dosage Forms

No information avaliable

Urotrast Indication

For the treatment of tetrahydrobiopterin (BH4) deficiency.

Urotrast Pharmacology

Tetrahydrobiopterin (BH4) is used to convert several amino acids, including phenylalanine, to other essential molecules in the body including neurotransmitters. Tetrahydrobiopterin deficiency can be caused by mutations in GTP cyclohydrolase 1 (GCH1), 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1), 6-pyruvoyltetrahydropterin synthase (PTS), and quinoid dihydropteridine reductase (QDPR) genes. These genes make the enzymes that are critical for producing and recycling tetrahydrobiopterin. If one of the enzymes fails to function correctly because of a gene mutation, little or no tetrahydrobiopterin is produced. As a result, phenylalanine from the diet builds up in the bloodstream and other tissues and can damage nerve cells in the brain. High levels of phenylalanine can result in signs and symptoms ranging from temporary low muscle tone to mental retardation, movement disorders, difficulty swallowing, seizures, behavioral problems, progressive problems with development, and an inability to control body temperature.

Urotrast Absorption

No information avaliable

Urotrast side effects and Toxicity

No information avaliable

Urotrast Patient Information

No information avaliable

Urotrast Organisms Affected

Humans and other mammals